Abstract：
There are limited data on the optimal choice of anticoagulation in multiple myeloma (MM) patients receiving immunomodulatory drugs (IMiDs). We conducted a propensity score-matched cohort study using the TriNetX database to compare the efficacy and safety of factor Xa inhibitors and warfarin in this patient population. Compared to warfarin, factor Xa inhibitors had a similar risk of deep vein thrombosis (hazard ratio [HR]: 1.11 [95% CI: 0.50-2.46]) or pulmonary embolism (HR: 1.08 [95% CI: 0.59-2.00]). There were no differences in the risk of gastrointestinal or intracranial bleeding. Factor Xa inhibitor-treated patients had lower all-cause mortality (HR: 0.56 [95% CI: 0.36-0.86]) compared with warfarin. These data suggest that factor Xa inhibitors had similar safety and efficacy compared with warfarin for MM patients on IMiDs.
摘要：
关于接受免疫调节药物（IMiDs）的多发性骨髓瘤（MM）患者抗凝治疗的最佳选择的数据有限。我们使用TriNetX数据库进行了倾向评分匹配的队列研究，以比较Xa因子抑制剂和华法林在该患者人群中的疗效和安全性。与华法林相比,因子Xa抑制剂具有相似的深静脉血栓形成(风险比[HR]:1.11[95%CI:0.50-2.46])或肺栓塞(HR:1.08[95%CI:0.59-2.00])风险.胃肠道或颅内出血的风险没有差异。与华法林相比，因子Xa抑制剂治疗的患者全因死亡率较低（HR：0.56[95%CI：0.36-0.86]）。这些数据表明，与华法林相比，因子Xa抑制剂对IMiD的MM患者具有相似的安全性和有效性。
